Once Weekly Carfilzomib Effective in Treatment-Naïve Multiple Myeloma
Multiple myeloma patients who received once-weekly carfilzomib with cyclophosphamide, dexamethasone had improved responses.
Multiple myeloma patients who received once-weekly carfilzomib with cyclophosphamide, dexamethasone had improved responses.
The largest study of T-lymphoblastic leukemia (T-ALL) ever conducted demonstrated “an excellent outcome” with standard four-drug induction.
Minimal residual disease (MRD) negativity is the greatest independent predictor of prognosis in mantle cell lymphoma.
Rituximab should be used as maintenance therapy for the treatment of young previously untreated patients with mantle cell lymphoma.
Addition of sorafenib to standard chemotherapy for the treatment of younger patients with acute myeloid leukemia (AML) is effective.
Lenalidomide induces the ubiquitination and degredation of casein kinase 1A1 (CSNK1A1) by the CRBN-CRL4 E3 ubquitin ligase.
Multiple myeloma treated with SAR650984 in combination with lenalidomide/dexamethasone see clinical benefit rate (CBR) of 65%.
Isolated testicular relapse in children with acute lymphoblastic leukemia (ALL) is associated with improved outcomes.
Disruption of tunneling nanotubules reduces the survival benefit that mesenchymal cells provide to primary acute lymphoblastic leukemia (ALL).
Adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma is clinically meaningful for progression-free survival.
Please login or register first to view this content.